search
Back to results

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis

Primary Purpose

Nasopharyngeal Cancers

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
rhGM-CSF
Compound Vitamin B12
Sponsored by
Wei LUO
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nasopharyngeal Cancers focused on measuring rhGM-CSF, Oral Mucositis, Primary Nasopharyngeal Cancers, Chemoradiotherapy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Grade II oral mucositis induced by chemoradiotherapy in patient with primary nasopharyngeal carcinoma.
  2. Receiving 68-72 Gray of radiation dose.
  3. Age between 18 and 65 years.
  4. KPS≥70.
  5. Patient who has given his/her written consent before any specific procedure of the protocol.

Exclusion Criteria:

  1. Severe uncontrolled infection.
  2. Pregnant or breast-feeding females.
  3. Allergy to this medicine.
  4. Diarrhea.

Sites / Locations

  • Sun Yat-sen University Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm A

Arm B

Arm Description

Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily. Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily Radiotherapy: Intensity modulated radiation therapy(IMRT) Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.

Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily Radiotherapy: Intensity modulated radiation therapy(IMRT) Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.

Outcomes

Primary Outcome Measures

The incidence of grade II and less oral mucositis at the end of treatment
Using the criteria of NCI CTCAE v3.0

Secondary Outcome Measures

Pain
Cumulative incidence and time of different grade,using the criteria of WHO,NRS
Cumulative incidence and time of grade III and more oral mucositis
Using the criteria of NCI CTCAE v3.0
Dysphagia
Cumulative incidence and time of different grade,using NCI CTCAE v3.0
Tumor response to chemoradiotherapy
Using the criteria of Response Evaluation Criteria in Solid Tumors1.1(RECIST1.1)

Full Information

First Posted
March 4, 2013
Last Updated
March 27, 2013
Sponsor
Wei LUO
search

1. Study Identification

Unique Protocol Identification Number
NCT01806272
Brief Title
Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
Official Title
A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Unknown status
Study Start Date
March 2013 (undefined)
Primary Completion Date
June 2014 (Anticipated)
Study Completion Date
August 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Wei LUO

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a open,randomized phase II trial comparing effectiveness and safety of local use of rhGM-CSF and Compound Vitamin B12 to Compound Vitamin B12 solution alone treating oral mucositis in primary nasopharyngeal cancer. The main end point is the incidence of grade II and less oral mucositis at the end of treatment.The hypothesis of the study is that the local use of rhGM-CSF and Compound Vitamin B12 can decrease the incidence of grade III and more oral mucositis at the end of treatment compared to local use of Compound Vitamin B12 alone.
Detailed Description
Inclusion Criteria: Grade II oral mucositis induced by chemoradiotherapy in patient with primary nasopharyngeal carcinoma. Receiving 68-72 Gray of radiation dose. Age between 18 and 65 years. KPS≥70. Patient who has given his/her written consent before any specific procedure of the protocol. Exclusion Criteria: Severe uncontrolled infection. Pregnant or breast-feeding females. Allergy to this medicine. Diarrhea. Outcome measures: Grade of oral mucositis:NCI Common Terminology Criteria for Adverse Events v3.0, NCI CTCAE v3.0 Pain: WHO,Numerical Rating Scale(NRS) Tumor response to chemoradiotherapy:Response Evaluation Criteria in Solid Tumors,RECIST1.1

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasopharyngeal Cancers
Keywords
rhGM-CSF, Oral Mucositis, Primary Nasopharyngeal Cancers, Chemoradiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A
Arm Type
Experimental
Arm Description
Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily. Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily Radiotherapy: Intensity modulated radiation therapy(IMRT) Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.
Arm Title
Arm B
Arm Type
Active Comparator
Arm Description
Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily Radiotherapy: Intensity modulated radiation therapy(IMRT) Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.
Intervention Type
Drug
Intervention Name(s)
rhGM-CSF
Other Intervention Name(s)
特尔立
Intervention Description
The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
Intervention Type
Drug
Intervention Name(s)
Compound Vitamin B12
Other Intervention Name(s)
贯新克
Intervention Description
Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Primary Outcome Measure Information:
Title
The incidence of grade II and less oral mucositis at the end of treatment
Description
Using the criteria of NCI CTCAE v3.0
Time Frame
7 weeks
Secondary Outcome Measure Information:
Title
Pain
Description
Cumulative incidence and time of different grade,using the criteria of WHO,NRS
Time Frame
12 weeks
Title
Cumulative incidence and time of grade III and more oral mucositis
Description
Using the criteria of NCI CTCAE v3.0
Time Frame
7 weeks
Title
Dysphagia
Description
Cumulative incidence and time of different grade,using NCI CTCAE v3.0
Time Frame
12 weeks
Title
Tumor response to chemoradiotherapy
Description
Using the criteria of Response Evaluation Criteria in Solid Tumors1.1(RECIST1.1)
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Grade II oral mucositis induced by chemoradiotherapy in patient with primary nasopharyngeal carcinoma. Receiving 68-72 Gray of radiation dose. Age between 18 and 65 years. KPS≥70. Patient who has given his/her written consent before any specific procedure of the protocol. Exclusion Criteria: Severe uncontrolled infection. Pregnant or breast-feeding females. Allergy to this medicine. Diarrhea.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wei LUO, M.D.
Phone
+862087343483
Email
luowei2@mail.sysu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wei LUO, M.D.
Organizational Affiliation
Sun Yat-sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei LUO, M.D.
Phone
+862087343483
Email
luowei2@mail.sysu.edu.cn

12. IPD Sharing Statement

Learn more about this trial

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis

We'll reach out to this number within 24 hrs